Survival Bump With Oral AML Maintenance

]]>(MedPage Today) -- ORLANDO--Overall survival (OS) in acute myelogenous leukemia (AML) improved by almost 10 months in patients who received the oral azacitidine agent CC-486 as maintenance therapy after attaining complete response, a randomized...